Όλο το DSpace

Πλοήγηση ανά Θέμα "beta-Lactams"

Αποτελέσματα 1-3 από 3

    • Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study 

      Harris P.N.A., Pezzani M.D., Gutiérrez-Gutiérrez B., Viale P., Hsueh P.-R., Ruiz-Garbajosa P., Venditti M., Tumbarello M., Navarro-Francisco C., Calbo E., Akova M., Giamarellou H., Oliver A., Almirante B., Gasch O., Martínez-Martínez L., Schwaber M.J., Daikos G., Pitout J., Peña C., Hernández-Torres A., Doi Y., Pérez F., Tuon F.F., Tacconelli E., Carmeli Y., Bonomo R.A., Pascual Á., Paterson D.L., Rodríguez-Baño J., del Toro M.D., Gálvez J., Falcone M., Russo A., Karaiskos I., Trecarichi E.M., Losito A.R., García-Vázquez E., Gómez J., Roilides E., Iosifidis E., Pournaras S., Prim N., Navarro F., Mirelis B., Origüen J., Juan R.S., Fernández-Ruiz M., Almela M., de la Calle C., Martínez J.A., Morata L., Larrosa N., Puig-Asensio M., Bou G., Molina J., González V., Bermejo J., Rucci V., de Gopegui E.R., Marinescu C.I., Fariñas M.C., Cano M.E., Gozalo M., Paño-Pardo J.R., Mora-Rillo M., Gómez-Zorrilla S., Tubau F., Tsakris A., Zarkotou O., Antoniadou A., Poulakou G., Souli M., Lowman W., Virmani D., Torre-Cisneros J., Machuca I., Gracia-Ahufinger I., Azap Ö.K., Helvaci Ö., Sahin A.O., Cantón R., Pintado V., Bartoletti M., Giannella M., Peter S., Hamprecht A., Badia C., Xercavins M., Fontanals D., Jové E., ESGBIS/REIPI/INCREMENT Group (2017)
      We describe regional differences in therapy for bloodstream infection (BSI) caused by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE). Patients (n = ...

    • Predominance of a methicillin-resistant Staphylococcus aureus clone susceptible to erythromycin and several other non-β-lactam antibiotics in a Greek hospital 

      Polyzou, A.; Slavakis, A.; Pournaras, S.; Maniatis, A. N.; Sofianou, D.; Tsakris, A. (2001)
      A clone of heterogeneously methicillin-resistant Staphylococcus aureus (MRSA) isolates susceptible to erythromycin, ciprofloxacin, clindamycin, co-trimoxazole, nitrofurantoin, rifampicin, tetracycline and vancomycin, ...

    • Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study 

      Kyriazopoulou E., Sinapidis D., Halvatzis S., Velissaris D., Alexiou N., Kosmas V., Adami M.-E., Kyprianou M., Kyprianou A., Stefos A., Lada M., Koutoukas P., Pavlaki M., Kyriakoudi A., Makina A., Gogos C., Niederman M.S., Giamarellos-Bourboulis E.J. (2020)
      Although analysis of retrospective studies has documented survival benefit from the addition of a macrolide to the treatment regimen for community-acquired pneumonia (CAP), no data are available to determine if there is ...